Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: zakaran who wrote (932)	7/5/2000 8:37:18 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

Zak, I don't have the whole story. It wasn't of sufficient interest to me to bother calling Elayne or Tamara or Karen to get it. 2 Massachusetts organizations had asked QLT for royalties. I believe it was quite early this year that QLT entered into a mutually acceptable agreement with the hospital. The other org'n - some ear and eye institute was a little more greedy and QLT has decided to use the court systems to settle the dispute. An out of court settlement is still possible; QLT could win; or QLT could end up paying what the institute is asking. OF those 3 outcomes, 2 are relatively positive for QLT; and the other is no worse than the status quo. Visudyne is still well on the way to becoming a blockbuster. There still isn't a competitor within 2 years of FDA approval. I still intend to hold my entire position for at least another 2 years, possibly longer. Ask me again 2 years from now. ;-) Ian.